Therapeutic potential for B-cell modulation in Sjögren's syndrome.
B-cell hyperactivity has been recognized for a long time in Sjögren's syndrome. This B-cell activation is firstly polyclonal but can progress to monoclonal B-cell lymphoproliferation. This article addresses the therapeutic potential of B-cell modulation in Sjögren's syndrome.
Mariette
Xavier
X
Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud 11, Le Kremlin Bicêtre, Institut Pour la Santé et la Recherche Médicale (INSERM) U 802, France. xavier.mariette@bct.aphp-paris.fr
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D015551:Autoimmunity / Q000276:immunology*; D053264:B-Cell Activating Factor / Q000097:blood; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D051379:Mice; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D012469:Salivary Glands / Q000378:metabolism; D012859:Sjogren's Syndrome / Q000097:blood / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D053264:B-Cell Activating Factor; D007155:Immunologic Factors; C505719:TNFSF13B protein, human; D000069283:Rituximab